– FRANCE, Aix-en-Provence – Affluent Medical, a French MedTech company specialized in innovative, minimally-invasive implants designed to restore key physiological functions in patients suffering from structural heart diseases, as well as urinary incontinence, today announced the closing of €10.3 Million in Private Placement Financing led by Truffle Capital alongside other investors including Head Leader Limited (China), Ginko Invest (Jean-François Le Bigot), Fate (Benoît Adelus), and Simone Merkle, a historic investor also participating.
The company also announced the appointment of Jean-François Le Bigot and Benoît Adelus to its Board of Directors to further bolster the team. Michel Finance, CEO of Affluent Medical, was also appointed board member and elected Chairman of the Board.
“We are very pleased to welcome Jean-François Le Bigot and Benoît Adelus to our board of directors. They bring decades of leadership in key areas, such as talent acquisition, strategy implementation, clinical development and financing in the medical field that are vital to our future operations and strategy.” said Michel Finance, Chairman and CEO.
He added: “Their expertise along with the €15.8 million in refinancing should allow Affluent Medical to make rapid progress on its clinical programs and its commitment to bring new-generation minimally-invasive medical devices to the market for the treatment of large unmet medical needs.”
The Private Placement Financing was taken out for gross proceeds of €10.3 million, €8 million via convertible bonds (of which €4 million were received in December 2019).
The Company intends to use the proceeds from the offering to fund its ongoing clinical activities in cardiology, and especially for the MINERVA First-In-Human clinical study of the Epygon Mitral valve, to complete the OPTIMISE II pivotal clinical study of KALIOS (adjustable mitral ring) and start a pilot / pivotal study of Artus (implantable urinary sphincter) in urology.
Affluent Medical has been granted two government-backed loans for a total of €2.2 million from the banks Société Générale and BNP PARIBAS as part of public measures to mitigate the economic impact of the Coronavirus. The two loans are interest-free and repayable either after one year or over a period of up to five years.
An innovation loan for €1 million was also granted by Bpifrance to finance R&D projects in cardiology. The loan carries an interest rate of 1.14% and will be repaid over a period of five years starting in September 2022.
Furthermore, following approval of the clinical study in Austria, Epygon received €2.3 million in grants in early May from the French public investment bank Bpifrance as part of the PSPC MIVANA project .
About Jean-François Le Bigot
Jean-François Le Bigot currently serves as CEO of Oncovita and Chairman of Ginko Invest. He was previously Chairman of Citoxlab Group (formerly CIT) that he joined in 1987. Over a period of more than 30 years, he developed and expanded Citoxlab which became a leading International CRO with more than 1500 employees. Under his leadership, Citoxlab acquired many CROs in North America and Europe. He successfully sold Citoxlab in 2019 to Charles River. He previously held executive positions at Sandoz Laboratories. Jean-François holds a PhD in Biomedical pharmacology.
About Benoit Adelus
Benoit Adelus has more than 30 years of experience in healthcare, MedTech, in vitro diagnostics, vaccines and animal health sectors where he led a number of successful companies that he developed significantly through innovation, international expansion and acquisitions in the US and China in particular. He has strong international experience having held different positions, from VP Commercial Operations, R&D to CEO in the US and Latin America. He led the IPO of bioMerieux on the Paris stock exchange in 2004 as CEO. He has extensive experience in LBOs, having led a total of four highly successful transactions and served as Chairman or Board Member of various Healthtech companies.
About Affluent Medical
Affluent Medical is a French MedTech company founded by Truffle Capital with the ambition to become a European leader in the treatment of heart and vascular diseases, which are the world’s leading cause of death, and of urinary incontinence, which today affects one in four adults. Affluent Medical develops innovative, next-generation minimally-invasive implants to restore key physiological functions in these areas. The company’s four major technologies are currently in preclinical and clinical phases, and a first medical device is expected to be launched by 2022.
For more information: www.affluentmedical.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.